MedAssets valuation is exceptionally attractive, says RW Baird Baird believes the valuation of MedAssets is exceptionally attractive and raised its price target to $25 from $24. The firm cited recent contract wins, expansions, and believes it will hit its above Street Q4 guidance. Shares are Outperform rated.
Healthways, MedAssets partner in new five-year agreement Healthways (HWAY) has partnered with MedAssets (MDAS) to expand patient access to the Dr. Dean Ornish Program for Reversing Heart Disease. Under the five-year agreement, Healthways has contracted with MedAssets as its sales partner to accelerate deployment of the Ornish Reversal Program to hospitals, health systems and physician organizations. The Ornish Reversal Program is the most scientifically proven platform in lifestyle medicine for treating and reversing heart disease and other chronic conditions.